Acknowledgments
We would like to thank Dr. Paul J. Coucke, Dr. Julie De Backer and Prof. Anne M. De Paepe for critical reading of the manuscript.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was funded by Jagiellonian University Medical College (Grant K/ZDS/00580).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Hoffjan S. Genetic dissection of marfan syndrome and related connective tissue disorders: an update 2012. Mol Syndromol 2012;2:47–58.10.1159/000339441Search in Google Scholar
2. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;7:476–85.10.1136/jmg.2009.072785Search in Google Scholar
3. Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev 2007;3:252–8.10.1016/j.gde.2007.04.006Search in Google Scholar
4. Bateman JF, Freddi S, Lamandé SR, Byers P, Nasioulas S, Douglas J, et al. Reliable and sensitive detection of premature termination mutations using a protein truncation test designed to overcome problems of nonsense-mediated mRNA instability. Hum Mutat 1999;13:311–7.10.1002/(SICI)1098-1004(1999)13:4<311::AID-HUMU8>3.0.CO;2-PSearch in Google Scholar
5. Eldadah ZA, Brenn T, Furthmayr H, Dietz HC. Expression of a mutant human fibrillin allele upon a normal human or murine genetic background recapitulates a Marfan cellular phenotype. J Clin Invest 1995;2:874–80.10.1172/JCI117737Search in Google Scholar
6. Schrijver I, Liu W, Odom R, Brenn T, Oefner P, Furthmayr H, et al. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet 2002;2:223–7.10.1086/341581Search in Google Scholar
7. Reinhardt DP, Ono RN, Notbohm H, Müller PK, Bächinger HP, Sakai LY. Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome. J Biol Chem 2000;16:12339–45.10.1074/jbc.275.16.12339Search in Google Scholar
8. Charbonneau NL, Carlson EJ, Tufa S, Sengle G, Manalo EC, Carlberg VM, et al. In vivo studies of mutant fibrillin-1 microfibrils. J Biol Chem 2010;32:24943–55.10.1074/jbc.M110.130021Search in Google Scholar
9. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 2004;2:172–81.10.1172/JCI200420641Search in Google Scholar
10. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003;4:2750–7.10.1074/jbc.M209256200Search in Google Scholar
11. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;11:1586–92.10.1172/JCI200422715Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston
